Trial record 16 of 510 for:    "cord blood"

Allogeneic Umbilical Cord Blood Therapy for Chronic TBI

This study has been withdrawn prior to enrollment.
(The research fund, which is yet to be raised and expected to take for a while)
Sponsor:
Information provided by (Responsible Party):
MinYoung Kim, M.D., Bundang CHA Hospital
ClinicalTrials.gov Identifier:
NCT01451528
First received: October 11, 2011
Last updated: April 2, 2014
Last verified: April 2014
  Purpose

This open label trial is conducted to investigate the efficacy and safety of umbilical cord blood therapy for chronic traumatic brain injury patients.

The study hypothesis is that the participants will show significant improvement in cognition and function after Umbilical cord blood (UCB) transplantation.


Condition Intervention
Traumatic Brain Injury
Biological: Allogeneic Umbilical Cord Blood

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Allogeneic Umbilical Cord Blood Therapy for Chronic Traumatic Brain Injury Patients

Resource links provided by NLM:


Further study details as provided by Bundang CHA Hospital:

Primary Outcome Measures:
  • Changes in Short-term Memory Function [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in Global Outcome [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Intelligence [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Frontal Lobe Function [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Traumatic Brain Injury-related Symptoms [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Attention [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Behavior [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Emotion and Personality [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Motor Function and Activities of Daily Living [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Brain Structure [ Time Frame: Baseline - 6 months ] [ Designated as safety issue: No ]
  • Changes in Brain Glucose Metabolism [ Time Frame: Baseline - 2 weeks ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: July 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allogeneic Umbilical Cord Blood
Allogeneic Umbilical Cord Blood Transplantation
Biological: Allogeneic Umbilical Cord Blood
Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
Other Name: Umbilical Cord Blood

Detailed Description:

Traumatic brain injury patients have been increasing due to various accidents. After acute therapeutic intervention, rehabilitation is the conventional main treatment with medication. However, in chronic stage, there seems to be some limitation in obtaining functional improvement in spite of comprehensive rehabilitation. Cell therapy like Umbilical cord blood (UCB) transplantation has showed promising results in many animal studies. The mechanism of such neurological improvement is not fully understood. Stem cells included in UCB are expected to secrete neurotrophic factors to enhance brain function. In addition, anti-inflammatory effects of UCB are suggested. Autologous UCB are not available in most of the cases in fact. The aim of this clinical trial is to determine the safety and efficacy of allogeneic UCB.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic Traumatic Brain Injury Patient (onset duration: over 6 months)
  • Glasgow Outcome Scale: 2, 3, 4, 5

Exclusion Criteria:

  • High risk of pneumonia or renal function deterioration after immunosuppressant
  • Possibility of drug hypersensitivity which is related to this study remedy
  • Intractable seizure disorder
  • Poor cooperation of guardian,including inactive attitude for rehabilitation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01451528

Locations
Korea, Republic of
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-712
Sponsors and Collaborators
Bundang CHA Hospital
Investigators
Principal Investigator: Minyoung Kim, M.D., Ph.D. CHA University
  More Information

No publications provided

Responsible Party: MinYoung Kim, M.D., Associate Professor, Bundang CHA Hospital
ClinicalTrials.gov Identifier: NCT01451528     History of Changes
Other Study ID Numbers: TBIUCB, 2011-141
Study First Received: October 11, 2011
Last Updated: April 2, 2014
Health Authority: Korea: Institutional Review Board

Keywords provided by Bundang CHA Hospital:
Umbilical Cord Blood
Allogeneic
Traumatic Brain Injury

Additional relevant MeSH terms:
Brain Injuries
Wounds and Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System

ClinicalTrials.gov processed this record on July 29, 2014